Navigation Links
InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
Date:4/24/2009

- Results inform selection of doses, regimens to be explored in Phase 2b study -

-- Phase 2b program anticipated to begin in summer 2009 --

COPENHAGEN, April 24 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that results from a 14-day Phase 1b clinical study of ITMN-191 (R7227) in combination with the current standard of care were presented today by Stefan Zeuzem, M.D., of the J.W. Goethe University, Frankfurt, Germany, in an oral presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. The study explored the use of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) for 14 days of treatment in hepatitis C virus (HCV) treatment-naive patients infected with HCV genotype 1. ITMN-191 is an HCV protease inhibitor being developed in collaboration with Roche.

Among the highlights of his presentation, Dr. Zeuzem reported:

  • The combination of ITMN-191 plus the standard of care for 14 days resulted in rapid and sustained reductions in HCV RNA.
  • Substantial antiviral activity was observed in both the q8h and q12h dosing cohorts; the most rapid declines in HCV RNA occurred in the ITMN-191 900 mg q12h dosing cohort.
  • Viral rebound was not observed in any patient receiving treatment with ITMN-191 plus Pegasys and ribavirin.
  • ITMN-191 plus standard-of-care therapy was safe and generally well tolerated.
  • The findings support the continued evaluation of ITMN-191-based combination regimens of twice-daily and three-times-daily dosing in patients with chronic HCV infection.

Dr. Zeuzem, protocol chair of the study, said, "Based on the t
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the ... 26, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. ... New York City . A ... under the investor relations section of Arena,s website at ...
(Date:9/22/2014)... -- According to the new market ... Media and Reagents), by Source, by type, by ... Testing, Research, Drug Discovery) - Analysis & Global ... studies the major market drivers, threats, opportunities, and ... tables and 64 figures spread through 225 pages ...
(Date:9/22/2014)... 22, 2014 CytRx Corporation (Nasdaq: ... in oncology, today announced that study designs and progress ... aldoxorubicin, a pivotal global Phase 3 clinical trial in ... 2b clinical trial in small cell lung cancer, will ... (ESMO) 2014 Congress being held September 26-30, in ...
Breaking Medicine Technology:Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6
... Texas--(BUSINESS WIRE)--May 15, 2007 - Reata,Pharmaceuticals, Inc. today ... 2007 issue of the journal Cancer Research showing ... for cancer,was highly effective in a rigorous animal ... signaling activity of STAT3, an,important target for new ...
... Presented at the Society for Investigative,Dermatology, FREEPORT, N.Y., ... new clinical research that the,8-oxo-guanine DNA glycosylase (OGG1) ... and TNF-alpha in UV,irradiated skin cells. The data ... Society for Investigative Dermatology, May 9 - 12,in ...
Cached Medicine Technology:RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds,Significant Promise for Treating Breast Cancer 2RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds,Significant Promise for Treating Breast Cancer 3AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1,Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV,Irradiated Skin Cells 2
(Date:9/22/2014)... A surprising new study pulls back the curtain on ... differences in payment and income between physicians who perform ... , Contrary to perception, the research indicates, the physician ... and other procedure-performing doctors. , The new findings counter ... pay per minute explains why doctors who perform procedures ...
(Date:9/22/2014)... Mozes HealthDay Reporter MONDAY, ... American parents are aware of online physician-rating sites, and more ... their children, according to a new national study. The ... -- further suggest that negative online ratings may dissuade parents ... recommended by a neighbor. Conversely, a positive online rating ...
(Date:9/22/2014)... South Asians living in Canada have a higher rate ... compared with while people, McMaster researchers have found. ... Canadian Medical Association Journal (CMAJ Open) and may ... the fastest-growing ethnic groups in the country is the ... Canada, comprising about three percent of the population. They ...
(Date:9/22/2014)... researchers have published a pilot study showing the ... people with multiple sclerosis (MS). Improvements were ... and pain. "Development and effectiveness of a ... Description and outcomes" was epublished ahead of print ... of MS Care (doi: 10.7224/1537-2073.2013-045). The authors ...
(Date:9/22/2014)... Two new prescription devices approved by the U.S. Food ... people with migraine headaches who don,t tolerate migraine medications ... -- the Cefaly -- is designed to prevent migraines, ... meant to be used when migraines first start, according ... looking for alternative migraine treatments. Because these devices aren,t ...
Breaking Medicine News(10 mins):Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2
... from several misconceptions that people had about aging. A popular ... the happiest days of people's lives occur when they're young ... ,While old age was equated with unhappiness for other people, ... their old age. In other words older people seem to ...
... it is evident that a man is very critical and is ... and is admitted// in a Shenzhen hospital. It is very evident ... SAR's Centre for Health Protection said that the victim lives in ... a Hong Konger residing in Shenzhen. He fell ill after he ...
... and figures seemingly indicate that the number of violent ... over the past year//. According to the figures that ... shows that the staff had reported 224 incidents of ... ,Unison an organization that represents the health workers, says ...
... Cancer researchers in UK exclaimed children now become fond of ... meat// and fish – after surveying about 200 pairs of ... strong in high-protein dishes such as beef, lamb, fish, bacon ... to taste vegetables and dessert more preferably. ,Mothers ...
... According to the study it was found that Implantable ... //. But they are very efficient in reducing the ... published in the American Heart Association rapid access journal ... were sicker and more prone to develop heart failure,’ ...
... seizures, or psychogenic seizures are often misdiagnosed as epileptic ... epilepsy is caused by the abnormal electrical activity in ... are similar to epileptic seizures, they can be difficult ... 13, 2006, issue of Neurology, the scientific journal of ...
Cached Medicine News:Health News:Attitudes About Aging Different from Reality 2Health News:Attitudes About Aging Different from Reality 3Health News:Violence Against NHS Staff On The Raise 2Health News:Defibrillators Can Only Put off Heart Failure but Cannot Prevent One 2Health News:Clues To Identify Psychological Seizures 2Health News:Clues To Identify Psychological Seizures 3
... and Fracture Table is a mobile, ... flexible, easy to use, articulated posturing ... orthopedic procedures. Radiolucent abductor bars, wedge-shaped ... exceptional imaging capability. OrthoVision folds into ...
... Field (PEMF) bone growth stimulation delivered by ... long bone and small bone nonunions. Physio-Stim ... brace, or clothing without lessening its effectiveness. ... compact, lightweight unit including success rates as ...
... implanted bone growth stimulator is a useful adjunct ... already planned or when patient compliance may be ... implanted, patients are assured of therapeutic treatment directly ... for up to 6 months. , ,The OsteoGen ...
Cannulated Interference Screws...
Medicine Products: